AstraZeneca's Optimistic Bet on Gene Therapy's Success
AstraZeneca is betting on the potential of adeno-associated viruses (AAVs) as a gene shipping system for gene therapy, despite the struggles faced by AAV companies in the industry. While other companies have shifted their focus to new technologies like CRISPR, AstraZeneca believes that AAVs still hold promise, particularly for developing drugs for ultra-rare diseases.